Show Menu

Antiretroviral Therapy: Cheat Sheet by

CDC Stage of HIV Disease

-Stage I: Acute HIV infection
-Stage II: Asympt­omatic HIV
-Stage III: Early Sympto­matic HIV
-Stage IV: Late Sympto­matic HIV
= A Consti­tut­ional Disease
= B Neurol­ogical Disease
= C Secondary Infections
-C1 AIDS defining
-C2 Other infections
= D Secondary Cancers
= E Other Conditions

Clinical Staging of Oral Manife­sta­tions of HIV

Adults and Adoles­cents (>15yo)
Children (<1­5yo):
No disease
No disease
Angular Chellitis, Recurrent oral ulcera­tions
Angular Chellitis, Linear gingival erythema, extensive warts, Recurrent oral ulcera­tions, Parotid enlarge
Persistent oral candid­iasis, Oral hairy leukop­lakia, Acute necrot­izing ulcerative stomat­itis, gingiv­itis, period­ontitis
Persistent oral candid­iasis (after 8wks), Oral hairy leukop­lakia, Acute necrot­izing ulcerative gingivitis or period­ont­itis.
Chronic (>1mo) orolabial HSV, Kaposi's sarcoma,
Chronic (>1mo) orolabial HSV, Karpo's Sarcoma, Non-Ho­dgkin's lymphoma

HIV-­related Oral Lesions:

- Fungal, Viral, Bacteria
- Kaposi's Sarcoma, Non-Ho­dgkin's Lymphoma
- Aphtho­us-like Ulcers, Lichenoid or drug reactions, Salivary Gland Disease

Oral Candid­ias­is:

Erythe­matous Chelitis

Oral Ulcers:

-Herpes Simplex Infection
-HPV Lesiosn
-Cytom­ega­lovirus Infection
-Aphthous Ulcers
-Necro­tizing ulcerative gingiv­itis/ period­ontitis
-Necro­tizing Stomam­titis (NS)
There are many different causes of oral ulceration in patients with HIV infection = Herpes simplex infection, Varicella zoster infection. Accurate diagnosis and approp­riate management of oral ulceration in patients with HIV infection generally result in complete healing of the ulcera­tion.

Aphthous Lesions Clinical Types

Topical Therapy:
Systemic Therapy:
Topical Cortic­ost­eroids
Triamc­ino­lone: 40 mg /ml (0.5 ml-1.0 ml injected bid)
Predni­sone: 0.5-1.0 mg/kg qd x 7-10d, then taper
Thalid­omide: 200 mg PO qd

Antire­tro­viral Cancer:

Nucleoside OR Nucleotide Reverse Transc­riptase Inhibitors (Nukes)
Non-nu­cle­oside Reverse Transc­riptase Inhibitors (non-n­ukes)
Protase Inhibitors
Fusion Inhibitors
Chemokine Receptor Antago­nists
Integrase Inhibitors
See Life cycle of HIV

Current Antire­tro­viral Targets


Reverse Transc­riptase Inhibi­tors:

Nucleoside Analogues Zidovudine (AZT, ZDV) Didanosine (ddI) Zalcit­abine (ddC) Stavudine (d4T) Lamivudine (3TC) Abacavir (ABC) Emtric­itabine (FTC)
Non-nu­cle­oside analogues: Nevirapine (NVP) delavi­rdine (DLV) Efavirenz (EFV) etravirine (ETV) rilpiv­irine (RPV)
Nucleotide analogue
Tenofovir (TFV)

Protease Inhibi­tors:

saquinavir (SQV)
ritonavir (RTV)
indinavir (IDV)
nelfinavir (NFV)
amprenavir (APV)
lopinavir (LPV)
fosamp­renavir (FPV)
atazanavir (ATV)
tipranavir (TPV)
darunavir (DRV)
dolute­gravir (DTG)

Reverse Transc­riptase Inhibi­tors:

Integrase Inhibitors
Fusion Inhibitor:
Entry Inhibi­tors:
ralteg­ravir (RAL)
fuzeon (T20)
maraviroc (MVC)
elvite­gravir (ELV)

NRTIs Mechanism of Action:

Nucleoside Analogs (like AZT):
Analog of thymidine, cytosine or guanine
Tripho­sph­ory­lated inside lympho­cytes to active compound.
Incorp­orate into growing HIV viral DNA strand by reverse transc­rip­tase.
Nucleotide Analogs:
tenofovir (TDF)
does NOT need to be tri-ph­osp­hor­ylated only di-pho­sph­ory­lated to activate compound.
After incorp­oration of NRTIs, viral DNA synthesis will be termin­ated.

Non-nu­cle­oside Reverse Transc­riptase Inhibi­tors:

Agents directly bind to reverse transc­riptase to inhibit transc­rip­tion.
NNRTIs do not require phosph­ory­lation to be active.

Protease Inhibitors (PIs) MOA:

Protease enzyme cleaves HIV precursor proteins into active proteins that are needed to assemble a new, mature HIV virus.
PIs bind to protease preventing the cleavage and inhibiting the assembly of new HIV viruses.

Fusion Inhibitor:

Chemokine Receptor Antago­nists:

Marviroc (Selze­ntry)
CCR5 or CXCR4 receptors on cell surface
Virus will bind to one of the 2 receptors (some pt virus will bind to either receptors)
Marviroc blocks viral entry at CCR5
Dosed 300mg BID= 150mg BID with P450 inhibi­tors. = 600mg BID with P450 inducers

Integrase Inhibitors

Ralteg­ravir (Isent­ress)
Dosed = 400mg BID (1tab BID)
No induction or inhibition on CYP450 enzymes or Pgp
Metabo­lized by UGT1A1 (glucu­ron­ida­tion) = Only affected by drugs that inhibit or induce UGTs (ie. rifampin)


No comments yet. Add yours below!

Add a Comment

Your Comment

Please enter your name.

    Please enter your email address

      Please enter your Comment.

          Related Cheat Sheets

          More Cheat Sheets by Carmilaa

          Introduction to Pharmacology Cheat Sheet
          Osteology of Maxilla and Mandible Cheat Sheet